First cancer. Now, Parkinson’s?

The idea that one disease is actually several, each driven by its own genetics and differing in everything from age of onset to response to drugs, made cancer the poster child for precision medicine. Now, a $4 million study announced on Monday aims to see whether a genetically informed precision-medicine approach might work for Parkinson’s, too.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Cancel my subscription. Your site is impossible to work with:
    1. You never remember my password and constantly need it resubmitted
    2. When I click “forgot your password” there is no response
    3.STAT is not a convenient site to work with

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy